Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

New study highlights difficulty of detecting gastric ulcer pain in horses (opens in a new tab)

news-medical.net · 2026-09-23

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of five check out. Two claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedA new study led by Australian veterinarians found it is difficult to identify pain in horses with gastric ulcers and showed that a proposed blood-based test was not the solution.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the tested LPS-induced PBMC IL-1β blood-cell protocol was not associated with EGUS status and lacked diagnostic utility. However, the headline framing that the study 'found it is difficult to identify pain in horses with gastric ulcers' goes beyond the supplied abstract evidence, which evaluates EGUS presence/severity and a candidate proxy biomarker rather than directly establishing pain-detection difficulty. The headline therefore outruns the more supportable body claim that this particular blood test was not a solution.

1

Study evidence

TLR2 agonist Pam3CSK4 stimulation produced IL-1β below the assay lower limit of quantification in all horses and was removed from final analysis.

“Venous blood was collected from 77 horses, PBMCs were isolated and stimulated with increasing concentrations of … lipopolysaccharide (LPS) to assess IL-1β production.”
Claim 2 of 5Not coveredThe researchers also reported no significant difference in facial pain scores between horses that responded to the test and those that did not, and said larger studies and horse-specific methods will be needed.View evidenceHide evidence

Why this verdict

The supplied abstract profile reports EGUS association testing and ROC diagnostic performance, but it does not report facial pain score analyses or a comparison of facial pain scores between IL-1β responders and non-responders. It also does not include the stated recommendation for larger studies and horse-specific methods. These points may exist in full text or article quotations, but they are not verifiable from the abstract-depth paper profile.

1

Study evidence

TLR2 agonist Pam3CSK4 stimulation produced IL-1β below the assay lower limit of quantification in all horses and was removed from final analysis.

“Venous blood was collected from 77 horses, PBMCs were isolated and stimulated with increasing concentrations of … lipopolysaccharide (LPS) to assess IL-1β production.”
Claim 3 of 5Not coveredThe article says the negative findings should not be interpreted as evidence that gastric ulcers do not cause pain, but rather that circulating blood-cell immune responses may not be sensitive enough to detect stomach-localized inflammation or pain.View evidenceHide evidence

Why this verdict

The abstract profile supports only that the tested circulating PBMC IL-1β response was not associated with EGUS and lacked diagnostic utility. It does not state that negative findings should not be interpreted as evidence that ulcers are painless, nor does it provide the specific explanation that circulating blood-cell responses may be too insensitive to detect stomach-localized inflammation or pain. That interpretation is plausible but not verifiable at abstract depth.

1

Study evidence

TLR2 agonist Pam3CSK4 stimulation produced IL-1β below the assay lower limit of quantification in all horses and was removed from final analysis.

“Venous blood was collected from 77 horses, PBMCs were isolated and stimulated with increasing concentrations of … lipopolysaccharide (LPS) to assess IL-1β production.”
Claim 4 of 5SupportedAdelaide University researchers tested whether immune cells from horse blood could provide a measurable signal of equine gastric ulcer syndrome (EGUS) by measuring interleukin-1 beta (IL-1β) after stimulation with substances designed to trigger an immune response.View evidenceHide evidence

As stated77 horses

Why this verdict

The supplied profile states that venous blood was collected from 77 horses, PBMCs were isolated, and cells were stimulated ex vivo with TLR agonists including LPS and Pam3CSK4 to assess IL-1β production as a candidate biomarker for EGUS. The institutional attribution to Adelaide University is not independently evidenced in the abstract profile, but the scientific method and sample size are supported.

1

Study evidence

TLR2 agonist Pam3CSK4 stimulation produced IL-1β below the assay lower limit of quantification in all horses and was removed from final analysis.

“Venous blood was collected from 77 horses, PBMCs were isolated and stimulated with increasing concentrations of … lipopolysaccharide (LPS) to assess IL-1β production.”
2

Study evidence

Stimulation of PBMCs with the TLR2 agonist Pam3CSK4 produced no measurable IL-1β signal in the sampled horses: all results were reported as below the assay LLOQ, leading to exclusion of the TLR2 arm from analysis.

“PBMCs were isolated and stimulated with increasing concentrations of TLR2 and TLR4 agonists (Pam3CSK4 and lipopolysaccharide (LPS)) to assess IL-1β production.”
Claim 5 of 5SupportedThe test failed to reliably distinguish horses with gastric ulcers from those without them, with no significant association between the blood-cell response and EGUS.View evidenceHide evidence

As stated64 horses in the final analysis; 59 (92.2%) had gastric lesions; only 25% showed a measurable response

Why this verdict

The profile supports the central claim: after exclusions, only 25% were LPS IL-1β responders, EGUS prevalence was 92.2%, no association was detected between IL-1β responder status and EGUS presence, and ROC analyses showed poor diagnostic discrimination for EGUS and subtypes. The exact '64 horses' and '59' counts are not directly reported in the supplied abstract-depth profile, but the main finding that the test did not reliably distinguish EGUS from non-EGUS horses is supported.

1

Study evidence

TLR2 agonist Pam3CSK4 stimulation produced IL-1β below the assay lower limit of quantification in all horses and was removed from final analysis.

“Venous blood was collected from 77 horses, PBMCs were isolated and stimulated with increasing concentrations of … lipopolysaccharide (LPS) to assess IL-1β production.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • TLR2/Pam3CSK4 stimulation arm: all Pam3CSK4-stimulated IL-1β results were below the assay lower limit of quantification and this arm was removed from final analysis.

    The story generally says immune cells were exposed to TLR agonists, but it does not specifically report the secondary TLR2 assay failure or that this arm was excluded from final analysis.

    From Ex vivo PBMC TLR2 (Pam3CSK4) stimulation

  • Important limitation: high EGUS prevalence in the analyzed cohort, 92.2%, limits comparison between horses with and without EGUS.

    Although the story reports the high prevalence figure in connection with the results, its listed caveats do not identify high EGUS prevalence as a limitation affecting comparison or diagnostic evaluation.

    From Prospective clinical cohort with ex vivo PBMC stimulation and diagnostic/association testing

  • Important limitation: only 25% of horses were LPS IL-1β responders after exclusions, reducing power to detect associations and contributing to imprecision.

    The story mentions that only 25% showed a measurable response, but it does not present this as a power or precision limitation. The paper profile flags this as interpretation-relevant, especially given the wide confidence interval.

    From Prospective clinical cohort with ex vivo PBMC stimulation and diagnostic/association testing

  • Abstract-depth limitation: the exact post-exclusion sample size and full assay details are not reported in the supplied abstract profile.

    The story gives a final-analysis sample size, but the supplied abstract profile says the exact post-exclusion sample size is not reported and that full methodological details are unavailable at abstract depth.

    From Prospective clinical cohort with ex vivo PBMC stimulation and diagnostic/association testing; Ex vivo PBMC TLR2 (Pam3CSK

4 things the story did carry across
  • Primary objective: test whether ex vivo PBMC IL-1β release after TLR4/LPS stimulation is associated with EGUS presence or severity and has diagnostic value as a potential biomarker/proxy.
  • Clinical cohort and methods: venous blood from 77 horses, PBMC isolation, ex vivo TLR agonist stimulation, IL-1β quantification, EGUS phenotyping, and association/ROC analyses.
  • Main result: no association between LPS-induced PBMC IL-1β responder status and EGUS presence, with poor diagnostic discrimination by IL-1β AUC.
  • Interpretive boundary: the paper profile supports a negative finding for this biomarker protocol, not a direct conclusion about whether EGUS causes pain or whether pain is generally hard to detect.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether ex vivo PBMC IL-1β release after TLR4 (LPS) stimulation is associated with EGUS presence/severity and has diagnostic value (ROC) as a potential biomarker/proxy for EGUS-associated pain.Prospective clinical cohort with ex vivo PBMC stimulation and diagnostic/association testingExpand

In plain English

In a clinical cohort of 77 horses with endoscopic gastric lesion phenotyping, peripheral blood mononuclear cells (PBMCs) were isolated and stimulated ex vivo with increasing concentrations of the TLR4 agonist lipopolysaccharide (LPS) to assess IL-1β release as a candidate biomarker for equine gastric ulcer syndrome (EGUS). TLR2 stimulation with Pam3CSK4 produced IL-1β below the assay lower limit of quantification (LLOQ) in all animals and was excluded. After exclusions for lameness and systemic inflammation, 25% of horses were classified as LPS IL-1β responders and EGUS prevalence was 92.2%. No association was observed between LPS-induced PBMC IL-1β response and EGUS presence (OR 0.47, 95% CI 0.049–6.2; p = 0.6). Receiver operating characteristic analysis showed poor diagnostic performance of IL-1β AUC for EGUS (AUROC 0.39, 95% CI 0.11–0.67), Equine Squamous Gastric Disease (ESGD; AUROC 0.30, 95% CI 0.10–0.49) and Equine Glandular Gastric Disease (EGGD; AUROC 0.56, 95% CI 0.43–0.68). The authors conclude the tested LPS-induced PBMC IL-1β release protocol was not associated with EGUS status in this cohort.

Key findings

  • TLR2 agonist Pam3CSK4 stimulation produced IL-1β below the assay lower limit of quantification in all horses and was removed from final analysis.
  • After exclusions for lameness and systemic inflammation, 25% of horses were classified as LPS (TLR4) IL-1β responders; overall EGUS prevalence in the analyzed cohort was 92.2%.25% responders; EGUS prevalence 92.2%
“Venous blood was collected from 77 horses, PBMCs were isolated and stimulated with increasing concentrations of … lipopolysaccharide (LPS) to assess IL-1β production.”
What this piece can’t prove
  • TLR2 (Pam3CSK4) stimulation yielded IL-1β below assay LLOQ in all samples and was excluded, limiting evaluation to TLR4 (LPS).
  • High reported EGUS prevalence (92.2%) in the analyzed cohort limits comparisons between horses with and without EGUS.
  • Only 25% of horses were LPS IL-1β responders after exclusions, which may reduce statistical power to detect associations (reflected by wide confidence intervals).
  • Abstract does not report the exact post-exclusion sample size or full methodological/assay details in the text provided.
2human in vivoAssess feasibility/analytic performance of ex vivo PBMC TLR2 (Pam3CSK4) stimulation to induce measurable IL-1β in horses (protocol viability for biomarker development).Ex vivo PBMC TLR2 (Pam3CSK4) stimulationExpand

In plain English

Ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) with the TLR2 agonist Pam3CSK4 failed to produce measurable IL-1β in this cohort: all Pam3CSK4-stimulated IL-1β measurements were below the assay lower limit of quantification (LLOQ) and the TLR2 arm was removed from the final analysis.

Key findings

  • Stimulation of PBMCs with the TLR2 agonist Pam3CSK4 produced no measurable IL-1β signal in the sampled horses: all results were reported as below the assay LLOQ, leading to exclusion of the TLR2 arm from analysis.
“PBMCs were isolated and stimulated with increasing concentrations of TLR2 and TLR4 agonists (Pam3CSK4 and lipopolysaccharide (LPS)) to assess IL-1β production.”
What this piece can’t prove
  • No information provided on whether technical failures, reagent potency, or alternative detection methods were investigated to explain universal non-detects.
  • Findings are reported at abstract depth; full-text details (if present) were not available in the supplied evidence and could affect interpretation of feasibility.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 35 candidate papers

Candidate

Pain in 4D: How Do Early Life Events Create Susceptibilities to Pain

Pain and Suffering in Farmed Animals · 2026 · Crossref

Source (opens in a new tab)

And 29 more candidates considered.